Novanta is trading 4.08% up at $169.99 after investors continued rewarding its August 5 earnings beat and stronger outlook.
- Second-quarter revenue reached $265.8 million, adjusted EPS was $0.89, and organic growth accelerated to 9.3%.
- Management raised full-year revenue guidance to $1.13–$1.14 billion and incorporated Riverpoint Medical’s expected contribution.
- The broader risk-on market, helped by softer July employment data, is providing additional support.